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Malic Enzyme 1 Absence in Synovial Sarcoma Shifts
Antioxidant System Dependence and Increases
Sensitivity to Ferroptosis Induction with ACXT-3102
Caitlyn B. Brashears1, Bethany C. Prudner1, Richa Rathore1, Katharine E. Caldwell2, Carina A. Dehner3,
Jane L. Buchanan4, Sara E.S. Lange1, Neal Poulin5, Jennifer K. Sehn3, Jason Roszik6, Dirk Spitzer2,7,
Kevin B. Jones8,9,10, Regis O’Keefe7,11, Torsten O. Nielsen5, Eric B. Taylor4,12,13, Jason M. Held1,7,14,
William Hawkins2,7, and Brian A. Van Tine1,7,15

Purpose: To investigate the metabolism of synovial sarcoma (SS)
and elucidate the effect of malic enzyme 1 absence on SS redox
homeostasis.
Experimental Design: ME1 expression was measured in SS
clinical samples, SS cell lines, and tumors from an SS mouse model.
The effect of ME1 absence on glucose metabolism was evaluated
utilizing Seahorse assays, metabolomics, and C13 tracings. The
impact of ME1 absence on SS redox homeostasis was evaluated by
metabolomics, cell death assays with inhibitors of antioxidant
systems, and measurements of intracellular reactive oxygen species
(ROS). The susceptibility of ME1-null SS to ferroptosis induction
was interrogated in vitro and in vivo.
Results: ME1 absence in SS was conﬁrmed in clinical samples, SS
cell lines, and an SS tumor model. Investigation of SS glucose
metabolism revealed that ME1-null cells exhibit higher rates of

Introduction
Synovial sarcoma (SS) is the most common translocation-driven
soft-tissue sarcoma (1). It is characterized by a gene fusion between
the transcription factor SS18 (formerly termed SYT) on chromosome 18 and one of three homologous genes (SSX1, SSX2, or SSX4)
on the X chromosome (2–4). The t(X;18) translocation has been
identiﬁed in 90% to 95% of all cases of SS and is pathognomonic for
the disease (5). There are approximately 900 to 1,000 cases per year
in the United States, accounting for 8% to 10% of all soft-tissue
sarcomas (6–8). Given the lack of highly effective FDA-approved
therapies for SS, the development of novel, targeted therapeutics is
warranted.
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glycolysis and higher ﬂux of glucose into the pentose phosphate
pathway (PPP), which is necessary to produce NADPH. Evaluation
of cellular redox homeostasis demonstrated that ME1 absence shifts
dependence from the glutathione system to the thioredoxin system.
Concomitantly, ME1 absence drives the accumulation of ROS and
labile iron. ROS and iron accumulation enhances the susceptibility
of ME1-null cells to ferroptosis induction with inhibitors of xCT
(erastin and ACXT-3102). In vivo xenograft models of ME1-null SS
demonstrate signiﬁcantly increased tumor response to ACXT-3102
compared with ME1-expressing controls.
Conclusions: These ﬁndings demonstrate the translational
potential of targeting redox homeostasis in ME1-null cancers and
establish the preclinical rationale for a phase I trial of ACXT-3102 in
SS patients.
See related commentary by Subbiah and Gan, p. 3408

Identiﬁcation of metabolic alterations that arise in malignancies
can lead to the development of new therapeutic targets. Overexpression of malic enzyme 1 (ME1) has been associated with more
aggressive cancer phenotypes (9–15). In addition, increased ME1
expression has been demonstrated to be both a prognostic and
a predictive marker for sensitivity to radiotherapy (14, 16–18).
To date, a recurrent loss of ME1 expression has never been reported in any cancer. ME1 catalyzes the reversible oxidative
decarboxylation of malate to pyruvate, yielding NADPH from
NADPþ (19–21). Several cytosolic enzymes, along with ME1, produce
NADPH, includingglucose-6-phosphate dehydrogenase (G6PD)
and 6-phosphogluconate dehydrogenase (6PGD) of the pentose
phosphate pathway (oxPPP), as well as isocitrate dehydrogenases
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(IDH; ref. 22). There are also enzymes in the one-carbontetrahydrofolate oxidation pathways that make a small contribution
to the cytosolic NADPH pool (23–25). Flux through the ME1
pathway produces NADPH levels equivalent to that of enzymes
within the oxPPP, implicating ME1 as a major cytoplasmic source
of NADPH (26, 27).
NADPH is an important reducing equivalent, providing electrons for antioxidant defense and reductive biosynthesis. Cytosolic
NADPH is used for redox metabolism in the glutathione and
thioredoxin antioxidant pathways. These pathways allow cells to
maintain reactive oxygen species (ROS) levels, which act as signaling molecules to support proliferation and survival (28). The
highly proliferative state of cancer leads to an increases in ROS
levels that can cause oxidative stress and potentially result in cell
senescence or death (29, 30). Cancer cells compensate for increased
ROS through the upregulation of antioxidant pathways, such as
the glutathione or thioredoxin systems. When ROS accumulates
above a threshold level, protein, lipid, and DNA oxidation can
occur; therefore, the balance between ROS production and clearance is tightly regulated.
Both the thioredoxin pathway and glutathione pathway are
disulﬁde reductase systems that control cellular redox homeostasis.
The thioredoxin system is composed of thioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH. Trx is important in reducing oxidized cysteine and cleaving disulﬁde bonds of surrounding
proteins with a CXXC motif (31). The glutathione system is composed of the tripeptide glutathione (y-glutamyl–cyteinyl–glycine) in
a reduced form (GSH) and an oxidized form (GSSG), as well as
GSSG reductase (GR), glutathione peroxidase (GPX), glutaredoxins
(Grx), and NADPH (32). Within the glutathione pathway, GPX
uses GSH as a reducing equivalent to neutralize intracellular peroxides such as H2O2. As a result, when the glutathione pathway is
hindered, H2O2 accumulates (33–35). De novo synthesis of both
GSH and Trx requires the intermediate precursor cysteine. Cystine,
the stable precursor, is imported via the cystine–glutamate exchanger xCT (SLC7A11). Intracellularly, cystine is reduced to cysteine,
which provides the key antioxidant component of both GSH and
Trx (36).
Inhibition or dysregulation of cysteine metabolism and/or cellular
antioxidant systems can lead to ROS-mediated cell death processes,
such as ferroptosis. Ferroptosis is a form of nonapoptotic cell death
that is characterized by iron dependency and overwhelming lipid
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Materials and Methods
Cell lines
The following human sarcoma cell lines were kindly provided:
SK-LMS-1, MG-63, HTB-93 (ATCC), SYO-1 (Dr. Akira Kawai, National Cancer Centre Hospital, Tokyo, Japan), Fuji (Dr. Kazuo Nagashima,
Hokkaido University School of Medicine, Sapporo, Japan), Aska-SS,
Yamata-SS, HS-SY-II (purchased from Riken BRC, deposited by
Dr. Naka Norifumi and Dr. Sonobe Hiroshi, Ibaraki, Japan), and
MOJO (Dr. K. Jones, University of Utah, Salt Lake City, UT). SYO,
Fuji, Aska-SS, Yamata-SS, MOJO, and HS-SY-II were authenticated by conﬁrming expression of SYT–SSX fusion gene by RT-PCR.
HTB-93 was isolated in 1974 morphologically resembles SS but
lacks the pathognomonic translocation that is classic for SS, making
it a tissue type control that does not represent translocation dependent SS biology (40). SK-LMS-1, MG-63, Aska-SS, HS-SY-II,
HTB-93, MOJO, SYO-1, and Yamata-SS cell lines were cultured
at 37 C in 5% CO2, in Dulbecco’s modiﬁed Eagle medium
(Life Technologies) supplemented with 10% FBS and penicillin–
streptomycin 100 (10,000U/mL) (Life Technologies) Fuji was
cultured in RPMI Medium 1640 (Life Technologies) supplemented
with 10% FBS and penicillin–streptomycin 100 (10,000U/mL)
(Life Technologies). Cell lines were tested for mycoplasma monthly
and conﬁrmed negative with the MycoAlert Mycoplasma Detection
kit (Lonza LT07-118). All cell lines were cultured for less than
6 months after thawing.
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Synovial sarcoma (SS) is the most common translocationdriven soft-tissue sarcoma. Although the driving gene fusion
between SS18 and the X chromosome is well characterized, there
are currently no therapies that speciﬁcally target the innate
biology of SS. Therefore, there is a need in the ﬁeld for
the development of targeted therapeutics. In this study, we have
identiﬁed SS as the ﬁrst cancer to exhibit a recurrent loss of malic
enzyme 1 (ME1). The absence of ME1 in SS causes signiﬁcant
shifts in redox homeostasis that result in increased susceptibility
to ferroptosis induction both in vitro and in vivo. These preclinical ﬁndings highlight the potential therapeutic applications
for targeting redox homeostasis in ME1-null tumors as well
as the potential translational efﬁcacy of ferroptosis inducing
agents, such as ACXT-3102.

peroxidation (37, 38). xCT (SLC7A11) is a cystine–glutamate antiporter and the main mechanism of extracellular cystine import
necessary for the maintenance of intracellular cysteine pools. Inhibition of xCT is a well-described mechanism of ferroptosis induction (37). Although upregulation of cysteine import and cellular
antioxidant systems are features of cancer metabolism may protect
from ferroptosis, the rewiring of iron metabolism in cancer can
predispose to ferroptotic cell death (39). The upregulation of iron
import and the expansion of the liable iron pool are features of cancer
metabolism that potentiate ROS accumulation, through the irondependent Fenton reaction, and cell death through ferroptosis (39).
Therefore, induction of ferroptosis has become an attractive target for
the development cancer therapeutics.
In this study, proﬁling of metabolic genes was performed to identify
possible metabolic vulnerabilities within SS. This revealed the ﬁrst
cancer, monophasic SS, that lacks expression of ME1. This study
demonstrates that ME1 absence drives a unique innate redox system.
The absence of ME1 expression in SS tumors results in a dependency
upon the oxPPP for the production of cytoplasmic NADPH, an
essential cellular antioxidant. Consistently, SS exhibits signiﬁcant
alterations in redox homeostasis, as SS is exquisitely sensitive to Trx
inhibition, whereas activity of the glutathione pathway is reduced.
Decreased glutathione pathway activity results in an increased concentration of intracellular H2O2. Concomitantly, ME1 absence drives
increases in the free labile iron pools. The accumulation of cellular ROS
and increases the labile iron pool result in increased sensitivity to
ferroptosis induction. Enhanced sensitivity to ferroptosis can be
exploited through inhibition of xCT by ACXT-3102 (Sigma-2/erastin)
both in vitro and in vivo. Additionally, not only is disruption of redox
homeostasis with xCT inhibition a valid translational target in SS, but
the response of xCT inhibition in this context is dependent upon the
ME1 expression status of the tumor. Taken together, disruption of the
innate redox biology in ME1-null cells could be harnessed as a useful
therapeutic target in SS.

Malic Enzyme 1 Absence Increases Ferroptosis Sensitivity

IHC
Formalin-ﬁxed parafﬁn-embedded slides were deparafﬁnized after
incubation at 65 C for 1 hour, rehydrated, and incubated in 3%
hydrogen peroxide for 10 minutes. Slides were heated in antigen
unmasking solution (Vector). Primary antibody (1:100 malic enzyme
1, ab97445, Abcam) was applied to each slide and incubated overnight
at 4 C. Biotinylated secondary antibody (1:100 goat anti-rabbit, BA10a00, Vector Laboratories, Inc) was applied and incubated at room
temperature for 30 to 40 minutes. After washing, ABC complex
(Vector Laboratories, Inc) was applied and incubated for 30 minutes.
DAB (Vector Laboratories, Inc) was then applied and allowed to
incubate 30 to 60 minutes. Slides were then immediately counterstained with hematoxylin 1 (Thermo Fisher Scientiﬁc Inc) and
mounted. IRB approval for the use of deidentiﬁed tissue samples was
obtained from Washington University in St Louis.
qRT-PCR
RNA was collected from cell lines and tumor samples using
NucleoSpin RNA/Protein Kit (740933, Machery-Nagel). cDNA was
synthesized using the High-Capacity cDNA Reverse Transcriptase
Kit (4368813, Applied Biosystems). Quantitative reverse transcription-PCR (qRT-PCR) was conducted using Power SYBR Green PCR
Master Mix (4367659, Applied Biosystems) on a CFX96 Touch
Real-Time PCR Detection System (Bio-Rad). Primers for qRT-PCR
were purchased from Integrated DNA Technologies. Sequences
for primers utilized were as follows: ME1, 50 -TCACCTCAACAAGGACTTGGC-30 (forward primer), 50 -AAGTCAGAGTTCAGATGCTCG-30 (reverse primer); human 18S rRNA, 50 -CTACCACATCCAAGGAAGCA-30 (forward primer), and 50 -TTTTTCGTCACTACCTCCCCG-30 (reverse primer). Cycling conditions were as
follows: Step 1, 95 C for 10 minutes; step 2, 95 C for 15 seconds;
step 3, 60 C for 60 seconds; repeat steps 2/3 39 times, for a total of
40 cycles. Quantiﬁcation of ME1 expression was conducted using
DDCq, using human 18S rRNA as a housekeeping gene.
ME1 activity assay
Cells were plated at 1106 in 10-cm dishes the day before the
assay was performed. Cells were collected and a cytoplasmic fraction was produced (Cayman #10009277). The cytoplasmic fraction
was then accessed according to the manufacturer’s protocol (Pyruvate
Assay Kit, ab65342; Abcam). This protocol was adapted by substituting the pyruvate enzyme mix with malate enzyme mix composed of 67 mmol/L triethanolamine, 3.3 mmol/L L-malate, 0.3 mmol/L
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b-NADPþ, and 5 mmol/L MgCl2 (25, 55). All other steps within the
manufacturer’s protocol were followed.
Lentiviral-mediated ME1 expression
The ME1 overexpression vector ME1/pBABE-puro (Plasmid
#49163) was purchased from Addgene as bacteria in an agar stab and
subsequently transformed into competent XL10 bacteria and puriﬁed
into plasmid DNA with Qiagen Plasmid Plus Midi Kit (12945Qiagen
Inc). TransIT-LT1 Transfection reagent (Mirus) was used for plasmid
transfection of retro-VSVG and pLECO, plasmid into Lenti-X 293T
cells (Takara). Viral supernatants were harvested and cells were
transduced at 40 MOI with viral particles. Transduced cells were
selected for and maintained by culturing in puromycin. ME1 knockdown lentiviral particles (Mission shRNA: TRCN0000064730,
TRCN0000064728, and TRCN0000064732) were purchased from
Millipore-Sigma. For the vector control MISSON pLKO.1-puro Nontarget shRNA control Transduction Particles were purchased from
Millipore-Sigma (SHC016V). Cells were transduced and selected per
manufacturer’s protocol.
Immunoassays
For analysis of ME1 expression (sc-100569, Santa Cruz), cells were
seeded at 3  105 in a 6-well plate 1 day prior to collection. On day of
collection, media were removed, and cells were washed 3 times with 1
PBS. Cells were collected and lysed per reagent protocol of 1 Cell Lysis
Buffer (9803, Cell Signaling Technology). Lysates were run on a
ProteinSimple Wes Capillary electrophoresis instrument using instrument default settings and manufacturer’s standard protocol. The
antibodies and dilutions were as follows: ME1 1:50 (SAB4501853
Millipore-Sigma).
Seahorse assays
Both the Seahorse cell energy phenotype and fuel ﬂex assays were
performed per manufacturer’s protocol (Agilent). Cells were seeded in
a Seahorse 96-well plate: SYO and FUJI at 40,000/well and HTB-93 at
30,000/well 12 hours prior to assay. After performance of the Seahorse
assay, cell counts were measured using YOYO-1 iodide (Y3601,
Thermo Fisher Scientiﬁc Inc) on the IncuCyte Zoom live-cell imaging
system and the Seahorse results were normalized to cell count.
Metabolomic assays
For whole metabolomic analysis, SYO-1 WT, Fuji WT, SYO-1 OE,
and Fuji OE were plated at 1  106 cells in a 10-cm dish in MEM. Media
were removed and replaced with fresh media containing 5 mmol/L
glucose and 2 mmol/L labeled glutamine for 4 hours. After the
incubation period, methanol metabolite extraction was performed
according to HMT metabolite extraction protocol. Metabolome analysis was performed by HMT using CE-TOFMS.
For U13C glutamine tracings, SYO-1 WT, Fuji WT, SYO-1 OE, and
Fuji OE were plated at 1  106 cells in a 10-cm dish in MEM. Media
were removed and replaced with U13C glutamine (Cambridge Isotope
Laboratories) media containing 5 mmol/L glucose and 2 mmol/L
labeled glutamine for 2, 4, or 8 hours. After the incubation period,
methanol metabolite extraction was performed according to the HMT
metabolite extraction protocol. Metabolome analysis was performed
by HMT using CE-TOFMS. The data were corrected for natural
abundance of C13.
For 1,2 13C glucose tracings, SYO-1 WT and SYO-1 OE were plated
at 1106 cells in a 10-cm dish in MEM. Three hours prior to
application of the tracing media, plates were washed with PBS, and
the media were refreshed with new MEM. Media were removed and
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Microarray
Synovial sarcoma samples are from gene-expression omnibus
(GEO) accession GSE20196 (41), and other sarcoma samples are from
GSE21050 (42), GSE23980 (43), and GSE20559 (44). Baseline and
insulin-sensitive cases were selected from studies involving subcutaneous abdominal fat (adipose) and/or vastus lateralis muscle (skeletal
muscle), from accessions GSE13070 (45), GSE20950 (46),
GSE13506 (47), GSE35411 (48), GSE6798 (49), and GSE18583 (50).
Raw CEL ﬁles were downloaded from GEO and processed using
BioConductor packages within the R statistical software environment
(http://www.R-project.org) (51). Array quality was assessed using the
package simpleaffy (52), and outlying arrays were identiﬁed and
excluded using the package mdqc (53). Log base 2 expression values
were determined using the package gcrma (54), with Affymetrix probe
set speciﬁcations. Data were median centered, such that the expression
value for each gene is relative to the median value across all specimens
in the cohort.
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replaced with 1,2 13C glucose (Cambridge Isotope Laboratories) at
5 mmol/L and 4 mmol/L glutamine for 24 hours. After the incubation
period, methanol metabolite extraction was performed according
to the HMT metabolite extraction protocol. Metabolome analysis
was performed by HMT using CE-TOFMS. The data were corrected
for natural abundance of C13.

3576 Clin Cancer Res; 28(16) August 15, 2022

Drug treatment and cell death assays
Nuclight Red cell lines were seeded at 20,000 cells in a 96-well plate
(SYO-WT, SYO-OE, Fuji WT, Fuji OE, HTB-93-WT, and HTB-93KDs) 1 day before assay. Cells were treated with either 25 mmol/L
G6PDi-1 (72 hours), 2 mmol/L BSO (24 hours), 1.2 mmol/L D9
(12 hours), 250 mmol/L deferoxamine (5 hours), erastin (dosage
indicated per cell line 48 hours), or 1 mmol/L ACXT-3102 (5 hours).
For rescue of erastin treatment with lipophilic antioxidants or ferrostatin, the dosages were as follows: 200 mmol/L Trolox, 100 mmol/L
a-tocopherol, and 10 mmol/L ferrostatin. Erastin rescue experiments
were treated for 72 hours. Phenol red-free media containing drug
concentration as well as 50 nmol/L of YOYO-1 iodide (Y3601, Thermo
Fisher Scientiﬁc Inc) cell death marker replaced growth media. Cell
death was measured via the YOYO-1 iodide probe, and live-cell
analysis was measured using Nuclight Red (4717, Sartorius). Cell
death was analyzed using IncuCyte FLR imaging system software
(Sartorius). For quantiﬁcation of death, YOYO-1 ﬂorescence was
normalized to total counts for each respective well. The drugs utilized
in these experiments were obtained as follows: BSO (14484, Cayman
Chemical), D9 (5921, Tocris), deferoxamine (S5742, Selleckchem),
Trolox (93510, Millipore-Sigma), a-tocopherol (1667600, MilliporeSigma), and ferrostatin (S7243, Selleckchem).
Iron and hydrogen peroxide assay
Nuclight Red cell lines were seeded at 20,000/well (SYO WT, SYOOE, FUJI WT, and FUIJI OE) in a 96-well plate. Cell lines were
incubated with each probe per the manufacturer’s protocol. Fe3þ
(Ferrum 430, Ursa BioScience), Fe2þ (FeRhoNox-1, Goryo Chemical),
and H2O2 (HYDROP, Goryo Chemical). Wells were imaged every 15
minutes over 1 hour, and analyzed using IncuCyte image analysis
software (Sartorius). Probe excitation was quantiﬁed using and IncuCyte FLR imaging system (Sartorius).
Lipid peroxidation assay
Cells were plated at 10,000 cells/well (SYO-1 WT, SYO-1 ME1 OE,
Fuji WT, Fuji ME1 OE, HTB93 WT, and HTB93 KDs) the day before
treatment with erastin. Cells were treated with erastin (1 mmol/L,
4 mmol/L, or 8 mmol/L) and incubated for 18 hours at 37C. After
incubation, the media were removed, and cells were treated with
10 mmol/L Image-IT (Invitrogen C10445) for 30 minutes. Cells were
washed with PBS, and ﬂuorescence was then measured on the plate
reader (Ex/Em: 488/510 nm). After completion of ﬂuorescent measurement, cell counts were measured using YOYO-1 on the IncuCyte
S3 live-cell imaging system, and the ﬂuorescent measurements were
normalized to cell count.
In vivo drug treatment
All animal experiments were under an approved protocol at
Washington University. Animal care followed Institutional Animal
Care and Use Committee standards.
ACXT-3102: Six- to seven-week-old athymic nu/nu female mice
were obtained from The Jackson Laboratories (Nu/J homozygous cat.
#002019). Mice were maintained at 5 animals per cage under humidity
and temperature-controlled conditions in a light/dark cycle that was
set at 12-hour intervals. Mice were injected subcutaneously in the
right ﬂank with a suspension of 1106 SYO-1 WT ME1-null or 1106
SYO-1 ME1 OE cells in an equal volume of Matrigel (Fisher Scientiﬁc).
Total volume was approximately 0.1 mL. Tumors were measured in
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NADPH measurements
SYO-WT, SYO-OE, HTB93-WT, and HTB93-KD3 cells were
seeded at 3 million cells per 10-cm dish 1 day prior to collection.
Samples were treated with physiologic glucose levels (5 mmol/L) or
without glucose for 3 hours. On the day of collection samples were
washed brieﬂy with ice-cold sterile water twice. After two washes cells
were ﬂash frozen on the 10-cm dish in liquid nitrogen prior to
extraction.
Extraction buffer was prepared by adding 2:2:1 methanol/acetonitrile/water, 0.1 M formic acid, and internal standards at 1 mg/mL each
(D4-Citric Acid, 13C5-glutamine, 13C5-glutamic acid, 13C6-lysine,
13C5-methionine, 13C3-serine, D4-succinic acid, 13C11-tryptophan,
and D8-valine; Cambridge Isotope Laboratories) to lyophilized cell
samples. Cells were scraped for 20 seconds and collected into Eppendorf tubes, ﬂash frozen in liquid nitrogen, and sonicated for 10
minutes. Samples were then placed on a rotating platform at –20 C
for 1 hour and centrifuged at 4 C for 10 minutes at 21,000  g. Cleared
metabolite extracts (300 mL) was transferred to fresh tubes for additional processing. An equal volume of each extract was pooled to
serve as a quality control (QC) sample, which was analyzed at the
beginning, end, and at regular intervals throughout the instrument
run. Extraction buffer alone was analyzed as a processing blank sample.
Metabolite extracts, the QC sample, and the processing blank were
evaporated to dryness using a speed vacuum.
For liquid chromatography mass spectrometry (LC-MS), the dried
metabolite extracts, QC sample, and processing blank sample were
reconstituted in 30 mL of acetonitrile/water (1:1, V/V), vortexed, and
centrifuged at 4 C for 10 minutes at 21,000  g. Samples were then
placed on a rotating platform at –20 C for 2 hours and centrifuged at
4 C for 2 minutes at 21,000  g. Samples were then transferred to
autosampler vials for analysis.
For LC chromatographic separation, 2 mL of reconstituted metabolite extracts, QC sample, and processing blank were run on a
Millipore SeQuant ZIC-pHILIC (2.1  150 mm, 5-mm particle size)
column with a ZIC-pHILIC guard column (20  2.1 mm) attached to a
Thermo Vanquish Flex UHPLC. Mobile phase comprised buffer A:
20 mmol/L (NH4)2CO3, 0.1% NH4OH and buffer B: acetonitrile. The
chromatographic gradient was run at a ﬂow rate of 0.150 mL/minute
as follows: 0–21 minutes-linear gradient from 80% to 20% buffer B;
20 to 20.5 minutes-linear gradient from 20% to 80% buffer B; and
20.5–28 minutes-hold at 80% buffer B. Data were acquired using
a Thermo Q Exactive MS operated in full-scan, polarity-switching
mode with a spray voltage set to 3.0 kV, the heated capillary held
at 275 C, and the HESI probe held at 350 C. The sheath gas ﬂow
was set to 40 units, the auxiliary gas ﬂow was set to 15 units, and the
sweep gas ﬂow was set to 1 unit. MS data acquisition was performed
in a range of m/z ¼ 70–1,000, with the resolution set at 70,000, the AGC
target at 10e6, and the maximum injection time at 200 ms.
TraceFinder 5.1 was utilized to identify metabolites based on m/z
and retention times that were determined by an in-house library of
standards. After attaining metabolite identiﬁcation and peak area
integration by TraceFinder, the NOREVA software (http://idrblab.
cn/noreva2017) was used for signal drift correction on a metabolite-tometabolite basis using multiple analyses of the QC sample throughout

the instrument run. Metabolite peak intensities were then normalized
to total ion signal.
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two dimensions with a digital caliper (Model 15077958, Fisher Scientiﬁc, Intl), and tumor volumes were calculated by the standard
formula of tumor volume ¼ length  width squared  0.5. Treatments
began when mean tumor volume reached 200 mm3. Animals were
randomly assigned to control group (WT ME1-null n ¼ 10, ME1 OE
n ¼ 10) or compound ACXT-3102–treated group (WT ME1-null n ¼
10, ME1 OE n ¼ 10). Controls received oral doses of the vehicle:
normal saline. ACXT-3102 was given orally at 60 mg/kg daily. Body
weights were obtained prior to dosing each day, and the dose of the
compound was adjusted accordingly. Mice were sacriﬁced when
tumors reached 2 cm3 or had ulcerated.

Data availability
For the RNA microarray, we used publicly available data sets from
GEO accession. For detailed description of data accession, refer to the
methods. The raw data ﬁles for the metabolomics analyses are available
as extended data tables. For access to other raw data ﬁles associated
with ﬁgures within this paper, please contact the corresponding
author. For access to the xCT inhibitor ACXT-3102 contact Accuronix
Therapeutics (https://accuronix.com/contact/).

Results
Synovial sarcoma lacks malic enzyme 1 expression
mRNA microarray analysis of a variety of metabolic enzymes in
human tumor samples was conducted to identify metabolic vulnerabilities in SS. The microarray revealed a relative loss of ME1 expression speciﬁcally in SS samples (Fig. 1A). ME1 protein expression was
analyzed by IHC in human tumor samples, including 20 SS and 20
leiomyosarcoma (LMS) patient tissue samples (Fig. 1B–E). Samples
were scored based on proportion of ME1-positive cells (0–3) and the
intensity of ME1 staining (0–3; Supplementary Fig. S1A–S1C). Prior to
scoring, the 20 SS patient tumors were stratiﬁed into their pathologic
classiﬁcations: monophasic (purely sarcoma), poorly differentiated,
and biphasic (containing epithelioid and sarcomatous regions). Of the
10 monophasic SS samples, ﬁve samples stained completely negative
for ME1 expression (Fig. 1B; Supplementary Fig. S1a–S1c), whereas
eight samples demonstrated limited, sporadic staining in individual
cells (Fig. 1C; Supplementary Fig. S1a–S1c). The poorly differentiated
SS samples exhibited positive staining for ME1. Interestingly, in all 7
biphasic tumor samples, the mesenchymal portion of the tumor lacked
ME1 expression, whereas the epithelial portion of the same tumor
exhibited stronger ME1 expression (Fig. 1D; Supplementary Fig. S1a–
S1c). The 20 LMS samples were all found to be positive for ME1
expression (Fig. 1E; Supplementary Fig. S1a–S1c). Finally, the quantiﬁed scoring values for monophasic SS and the spindled component of
biphasic SS were each signiﬁcantly lower than the LMS samples
(Supplementary Fig. S1c).
To further conﬁrm the absence of ME1 expression within other SS
models, mRNA and protein expression was analyzed in transgenic
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Lack of malic enzyme 1 favors a glycolytic phenotype with
concomitant upregulation of the oxPPP in SS
Previous studies have demonstrated that ME1 knockdown cells are
sensitized to rapid cell death with glucose withdrawal (59). To determine if this phenotype is similar in tumors that innately lack ME1
expression, the two major energy-producing pathways, glycolysis and
oxidative phosphorylation (OXPHOS), were measured using an energy phenotype assay in ME1-null cell lines (HS-SY-II WT, SYO-1 WT,
and Fuji WT) and in isogenic ME1-overexpression cell lines (HS-SY-II
OE, SYO-1 OE, and Fuji OE; Supplementary Fig. S4a and S4b).
Comparing oxygen consumption rate (OCAR) with the extracellular
acidiﬁcation rate (ECAR) gives an understanding of the energetic
phenotype in cells. WT ME1-null cell lines were found to have a less
energetic phenotype than cell lines that express ME1 (ME1OE; Fig. 2A; Supplementary Fig. S5). In contrast, the opposite
phenotype was found in ME1-knockdown (ME1-KD) cells, where
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Statistical analysis
Data were analyzed using GraphPad Prism 7 Software. In vitro
protein expression, cell death, activity assay, uptake assays, lipid
peroxidation, and labile iron data are expressed as mean  standard
deviation and Student t test for the individual group comparison.
Statistical analysis for in vivo study data was performed by analysis
of variance for multiple-group comparison and two-way ANOVA for
the individual group comparison with data expressed as standard
error of the mean.  , P < 0.05;  , P < 0.01;  , P < 0.001;  , P < 0.0001
were considered to represent statistically signiﬁcant group differences.

SS18–SSX mouse tumor samples and in established SS cell lines (56, 57).
Twenty-one samples were analyzed for mRNA expression: 18 synovial
sarcoma samples (9 SSX1 and 9 SSX2 fusion cases) compared with
three nontranslocation associated samples (mesenchymal stem cells,
MG-63, and SK-LMS-1). All synovial sarcoma samples lacked mRNA
expression of ME1, whereas the nontranslocation samples all exhibited
ME1 mRNA expression (Fig. 1F). Additionally, the TCGA database
was queried for mRNA transcript levels of ME1 in a cohort of SS,
dedifferentiated liposarcoma (DDLPS), LMS, myxoﬁbrosarcoma
(MYXO), and undifferentiated pleomorphic sarcoma (UPS; ref. 58).
SS was the only sarcoma of this cohort that exhibited signiﬁcantly
lower mRNA expression of ME1 when compared with the other
sarcoma subtypes (Supplementary Fig. S2). Finally, methylationspeciﬁc PCR was performed to investigate the mechanism of ME1
mRNA-null expression. Methylation status of the ME1 promoter was
compared in MG-63 (osteosarcoma), SK-LMS-1 (LMS), and two SS
cell lines (SYO-1 and Fuji; Supplementary Fig. S3). These data
demonstrated signiﬁcant methylation of the ME1 promoter in cell
lines that lack expression of ME1 (SYO-1 and Fuji), but not in cells that
express ME1 (Supplementary Fig. S3).
To correlate protein expression with mRNA levels, ME1 expression
in six synovial sarcoma cell lines (SYO-1, Fuji, MOJO, Yamata-SS,
Aska-SS, and HS-SY-II) was compared with ME1 expression in two
sarcoma cell lines (MG-63 and SK-LMS-1) and an SS cell line that lacks
the pathognomonic t(X;18) translocation (HTB-93; Fig. 1G). All
translocation-containing SS cell lines did not have ME1 expression
as compared with MG-63, SK-LMS-1, and HTB-93 (Fig. 1G). Furthermore, samples lacking ME1 expression showed no ME1 enzyme
activity, whereas samples with conﬁrmed ME1 expression demonstrated strong enzymatic activity (Fig. 1H). The known, relevant
genetics for each cell line are included in Supplementary Table S1.
Recently, Barrot and colleagues proposed a novel cell of origin for
SS, the periosteal progenitor cell (1). Due to this ﬁnding, we hypothesized that the ME1-null expression could be inherited from this
proposed cell of origin. Using three independent human periosteal cell
lysates and a mouse model of synovial sarcoma derived from periosteal
progenitor cells (n ¼ 7) in vivo, we demonstrated that ME1 is not
expressed in the proposed cell lineage of origin (Fig. 1I).
Taken together, these data demonstrate that the absence of ME1
expression is consistent across multiple sample sets of SS human cell
lines, SS tissue samples, and tumors from SS transgenic mouse models.
Furthermore, ME1-null expression likely originates from the cell of
origin, suggesting that ME1 absence is the innate biology of the
hypothesized periosteal progenitor cells from which SS is derived.
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(Fig. 2J). Additionally, mass isotopomer distributions and abundance of downstream products of nucleic acid synthesis demonstrate
that steady-state levels are equivalent in WT ME1-null and ME1-OE
cells, indicating that the noted change in lactate labeling is not
attributable to alterations in nucleotide synthesis (Supplementary
Fig. S8). Altogether, these data indicate that cells that lack expression
of ME1 exhibit reduced glucose oxidation and increased ﬂux of
glucose through glycolysis and the oxPPP.
G6PD inhibition leads to cell death in ME1-null SS
Glucose shunted to the oxPPP in ME1-null cells allows for NADPH
to be generated even in the absence of ME1 (63). Due to differential
glucose utilization in SS WT ME1-null as compared with ME1-OE cell
lines, NADPH abundance was analyzed in 5 mmol/L glucose and
glucose withdrawal conditions. In the SYO-1 WT ME1-null cell line,
when glucose is withdrawn, intracellular levels of NADPH are significantly depleted relative to NADPH levels in 5 mmol/L glucose media
(Fig. 3A). In contrast, in the SYO-1 ME1 OE cell line, glucose
withdrawal did not result in signiﬁcant reductions in the intracellular
levels of NADPH (Fig. 3A). Additionally, in the ME1-expressing cell
line HTB-93 glucose withdrawal resulted in a statistically signiﬁcant
reduction in NADPH levels (Fig. 3B). Whereas knockdown of ME1 in
HTB-93 resulted in an enhanced reduction of NADPH levels in the
presence of glucose withdrawal (Fig. 3B).
To exploit the reliance of WT ME1-null cells on the oxPPP, G6PD
was pharmacologically inhibited by G6PDi-1, a novel, noncompetitive,
allosteric inhibitor of G6PD (64). Inhibiting G6PD resulted in a
signiﬁcant induction of cell death in SYO-1 WT ME1-null cells,
whereas ME1 expression provided signiﬁcant protection from cell
death (Fig. 3C). Similarly, ME1-expressing HTB-93 WT cells exhibited signiﬁcantly less cell death with inhibition of G6PD compared
with the HTB-93 ME1 KD cell lines (Fig. 3D). These results further
support the hypothesis that WT ME1-null cells rely on the oxPPP for
NADPH production and survival.
ME1 absence in SS results in altered redox homeostasis and iron
redox status
NADPH is an essential cofactor in the recycling of redox antioxidant systems. Because NADPH production appears to be shifted to the
oxPPP in WT ME1-null cells, metabolic analysis was performed to
identify if this shift could affect levels of GSH and GSSG. Analysis of
SYO-1 WT ME1-null and Fuji WT ME1-null global metabolite proﬁles
revealed notable differences in the GSH and GSSG pools relative to
SYO-1 ME1 OE and Fuji ME1 OE. Comparing GSH to GSSG in WT
ME1-null versus ME1 OE SS cell lines, the total amount of GSH is
much lower in WT ME1-null cells relative to ME1 OE cells (Fig. 4A
top), whereas total levels of GSSG remained unchanged between
the two groups (Fig. 4A, bottom). To investigate the mechanism

Figure 1.
SS lacks malic enzyme 1 expression. A, RNA microarray of metabolic enzymes in human tissue samples including SS, LMS, DDLPS, normal adipose tissue (adipose),
normal skeletal muscle (Skel Mus), and UPS. B, Representative images of 20 SS and 20 LMS patient samples stained with hematoxylin and eosin (top) and anti-ME1
counterstained with hematoxylin (bottom), including (B) representative image of monophasic SS with conventional histology; (C) representative image
of monophasic SS exhibiting limited, sporadic anti-ME1 staining; (D) representative image of biphasic SS; and (E) representative image of LMS, which
served as a positive control for anti-ME1. F, qRT-PCR of ME1 in 21 sarcoma samples: 3 nontranslocation samples, 9 SS18:SSX1 SS samples, and 9 SS18:SSX2 SS
samples.    , P < 0.001. G, Protein expression of ME1 in osteosarcoma (MG-63), leiomyosarcoma (SK-LMS-1), and 7 SS cell lines (HTB-93, SYO-1, Fuji, MOJO,
Yamata-SS, Aska-SS, and HS-SY-II). Cell lysates were analyzed with the Simple Protein Wes system. Band density differences were plotted as ME1 area under the
curve normalized to total protein in the capillary (representative n ¼ 3). Data are represented as mean  SD;    , P < 0.001. H, Enzymatic activity of ME1
in osteosarcoma (MG-63), leiomyosarcoma (SK-LMS-1), and SS cell lines (HTB-93, SYO-1, Fuji, MOJO, Yamata-SS, Aska-SS, and HS-SY-II). Data are represented
as mean  SD (n ¼ 3);    , P < 0.001. I, Protein expression of ME1 in periosteal cell lysates (n ¼ 3) and tumors from SSX:SS18 spontaneous mouse tumors (n ¼ 7).
Mouse muscle tissue was used as positive control. Cell lysates were analyzed with the Simple Protein Wes system. Band density differences were plotted as ME1
area under the curve normalized to total protein in the capillary. Data, mean  SD;    , P < 0.001.
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ME1 knockdown in HTB-93 cells caused a decrease in energetic
phenotype (Fig. 2B; Supplementary Fig. S5). These data suggest that
ME1-null cells are more glycolytic than oxidative.
In order to better understand the underlying metabolic alterations
that lead to a less energetic phenotype in ME1-null cells, additional
Seahorse assays were performed to speciﬁcally evaluate changes in
glycolysis and OXPHOS. A glycolytic rate assay was performed to
compare the rate of glycolysis in cells that lack ME1 and ME1-OE cells,
which demonstrated that WT ME1-null cells are signiﬁcantly more
glycolytic than ME1-OE cells (Fig. 2C; refs. 60, 61). This led to the
hypothesis that the reduced OCAR reliance in WT cells could be due to
reduced glucose oxidation in the context of ME1 absence. To test this
hypothesis, we performed a fuel ﬂex assay, which demonstrated that
WT ME1-null cells do not oxidize glucose when compared with ME1OE cells (Fig. 2D). These data indicate that in ME1-null cells, the
glucose that is shunted through glycolysis and is not oxidized through
the mitochondria (Fig. 2C and D).
Because WT cells preferentially utilize glucose in glycolysis instead
of shunting it to the mitochondria for OXPHOS, a global metabolite
proﬁle on SS WT ME1-null and ME1-OE cell lines was performed
(Supplementary Table S2). The analysis demonstrated signiﬁcant
differences in oxPPP pathway metabolites between WT and OE cell
lines. The amount of total beginning substrates within this pathway
(glucose-6-phosphate and 6-phosphogluconic acid) do not change
between WT ME1-null and ME1 OE cell lines (Figs. 2E and F), but the
later substrates (ribulose-5-phosphate and ribose-5-phosphate) are
increased signiﬁcantly in WT ME1-null cell lines relative to ME1-OE
cell lines (Fig. 2G and H). Similarly, unbiased pathway analysis of the
global metabolite proﬁle revealed statistically signiﬁcant changes in the
PPP in SYO-1 and Fuji WT ME1-null relative to ME1-OE cells
(Supplementary Fig. S6a–S6b). To examine the functionality of the
enzymes within the oxPPP pathway, the activity of G6PD and 6PGD,
the two main NADPH-producing enzymes, was assessed. Based on
these assays, activity of G6PD and 6PGD did not change in the context
of ME1-OE (Supplementary Fig. S7a and S7b).
Although accumulation of downstream substrates may indicate
increased ﬂux through the oxPPP, it may alternatively suggest
reduced ﬂux through downstream pathways. It was hypothesized
that the WT ME1-null cells have increased ﬂux through the oxPPP
relative to ME1-OE cells. In order to more deﬁnitively test this
hypothesis, a 1,2-13Cglucose tracing experiment was performed (62).
1,2-13Cglucose that ﬂuxes through glycolysis produces mþ2 labeled
lactate, whereas 1,2-13C glucose that ﬂuxes through the PPP produces mþ1 labeled lactate. Comparison of the proportion of mþ2
lactate with mþ1 lactate produced a relative ﬂux estimate of glucose
ﬂux through the PPP (Fig. 2I; ref. 62). WT ME1-null cells exhibit
signiﬁcantly higher ratios of mþ1/mþ2 lactate relative to ME1-OE
cells, suggesting increased oxPPP ﬂux in the absence of ME1
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Figure 2.
Lack of malic enzyme 1 favors a glycolytic phenotype with concomitant upregulation of oxPPP in SS. A, Cell energy phenotype of ECAR vs. oxygen consumption rate
(OCR) in ME1-null SS cell lines (SYO-1 WT, Fuji WT, HS-SY-II WT) and ME1 overexpression cell lines (SYO-1 OE, Fuji OE, HS-SY-II OE). Data, mean  SD (n ¼ 3). Arrows
indicate direction of change upon ME1 overexpression. B, Cell energy phenotype of ECAR vs. OCR in ME1-expressing SS (HTB-93 WT) and ME1 knockdown cell line
(HTB-93 KD1). Data, mean  SD (n ¼ 3). Arrows indicate direction of change upon ME1 knockdown. C, Glycolytic rate assay in ME1-null SS cell lines (SYO-1 WT and Fuji
WT) and ME1 overexpression cell lines (SYO-1 OE and Fuji OE). Data, mean  SD (n ¼ 3);    , P < 0.0001. D, Mitochondrial fuel ﬂex assay showing the percentage of
oxygen consumption from glucose fuel source in ME1-null SS cell lines (SYO-1 WT and Fuji WT) and ME1 overexpression cell lines (SYO-1 OE and Fuji OE). Data, mean 
SD (n ¼ 3);    , P < 0.0001;   , P < 0.01. E, Metabolite levels (pmol/106 cells) of upper pentose phosphate metabolite glucose-6-phosphate in ME1-null SS cell lines
(SYO-1 WT and Fuji WT) and ME1 overexpression cell lines (SYO-1 OE, Fuji OE). Data, mean  SD (n ¼ 6); NS, P > 0.5. F, Metabolite levels (pmol/106 cells) of upper
pentose phosphate metabolite 6-phosphogluconic acid in ME1-null SS cell lines (SYO-1 WT, Fuji WT) and ME1 overexpression cell lines (SYO-1 OE and Fuji OE).
Data, mean  SD (n ¼ 6); NS, P > 0.5. G, Metabolite levels (pmol/106 cells) of lower pentose phosphate metabolite ribulose-5-phosphate in ME1-null SS cell lines
(SYO-1 WT and Fuji WT) and ME1 overexpression cell lines (SYO-1 OE, Fuji OE). Data are represented as mean  SD (n ¼ 6);   , P < 0.01;    P < 0.001. H, Metabolite
levels (pmol/106 cells) of lower pentose phosphate metabolite ribose-5-phosphate in ME1-null SS cell lines (SYO-1 WT and Fuji WT) and ME1 overexpression cell
lines (SYO-1 OE and Fuji OE). Data, mean  SD (n ¼ 6);   , P < 0.01;    , P < 0.001. I, Tracing diagram depicting 1,2-13C glucose labeling of substrates in glycolysis and
PPP to produce m þ 1 and m þ 2 labeled lactate. J, Fraction of m þ 1/m þ 2 lactate from 1,2-13C glucose in SYO-1 WT compared with SYO-1 OE. Data, mean  SD (n ¼ 4);

, P < 0.0001.
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Figure 3.
G6PD inhibition leads to cell death in ME1-null SS. A, NADPH levels in SYO-1 WT ME1-null and SYO-1 ME1 OE in the presence of glucose (þ) and under glucose
withdrawal (). Data, mean  SD (n ¼ 3);  , P < 0.05; NS, P > 0.05. B, NADPH levels in HTB-93 WT and HTB-93 ME1 KD3 in the presence of glucose (þ) and under
glucose withdrawal (). Data, mean  SD (n ¼ 3);  , P < 0.05. C, In vitro cell death response to G6PDi-1 inhibition of glucose-6-phosphate dehydrogenase in SYO-1 WT
ME1-null and SYO-1 ME1 OE. Data, mean  SD (n ¼ 3);   , P < 0.01. D, In vitro cell death response to G6PDi-1 inhibition of glucose-6-phosphate dehydrogenase in
HTB-93 WT, HTB-93 ME1 KD2, and HTB-93 ME1 KD3. Data, mean  SD (n ¼ 4);  , P < 0.01;    , P < 0.001.

underlying the change in total GSH levels, a universal glutamine tracer
was utilized to evaluate GSH synthesis from glutamine and turn over
into GSSG. The percent of glutamine labeled GSH and GSSG in the
total pool, denoted by m þ 10, m þ 5, or m þ other labeling, was
compared in SS WT ME1-null and SS ME1 OE cell lines. The percent
of labeled GSH in SYO-1 (Fig. 4B, top) and Fuji (Fig. 4C, top) within
the total pool was less in WT ME1-null cells relative to ME1 OE cells.
Additionally, the accumulation of glutamine incorporation over 2, 4,
and 8 hours is higher in ME1-OE cells when compared with WT ME1null cells, suggesting increased rates of GSH synthesis from glutamine.
Similarly, total glutamine labeling of GSSG in SYO-1 (Fig. 4B, bottom)
and Fuji (Fig. 4C, bottom) was reduced in WT ME1-null cells relative
to ME1 OE cells (Supplementary Table S3). However, no conclusions
can be drawn regarding the rate of GSH to GSSG turn over from this
tracing experiment. Taken together, these data demonstrate that SS
with an innate biology lacking ME1 expression exhibits signiﬁcant
reductions in their total GSH levels and likely reduced de novo
synthesis of GSH from glutamine.
Due to the altered pools of GSH, it was hypothesized that treating
SS with buthionine sulphoximine (BSO), an inhibitor of gammaglutamylcysteine ligase, would induce death by further disrupting
the glutathione pathway. Contrary to this hypothesis, treatment
with BSO only induced signiﬁcant cell death in ME1-expressing
cell lines (Fig. 4D; Supplementary Fig. S9a). Treatment of trans-
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fection control cell lines with BSO conﬁrmed that the change in
sensitivity was due to ME1 expression and was unrelated to the
vector (Supplementary Fig. S9b–S9c). Due to this unexpected result,
overall thiol amounts were evaluated upon BSO treatment. Thiol
amounts indicated that with BSO treatment WT ME1-null cells
were more capable of increasing the overall abundance of thiols
when compared with ME1-OE cells (Fig. 4E and F). Furthermore,
on target activity of BSO was conﬁrmed utilizing GSH-speciﬁc
ﬂuorescent probes. These data demonstrated that treatment with
BSO resulted in signiﬁcant reductions in cytoplasmic GSH (Supplementary Fig. S10). From these data it was hypothesized that an
increase in overall thiol amount could be related to the thioredoxin
antioxidant system. To evaluate the thioredoxin system, we compared sensitivity to a potent thioredoxin inhibitor (D9) in SS WT
ME1-null and SS ME1 OE (65). D9 treatment induced signiﬁcant
levels of cell death in WT ME1-null cell lines and not in ME1 OE
cell lines (Fig. 4G). Similarly, ME1 KD cell lines (HTB-93 KD)
exhibited signiﬁcantly increased cell death with D9 inhibition of
thioredoxin reductase compared with ME1-expressing cell line
HTB-93 (Fig. 4G; Supplementary Fig. S9d). Treatment of vector
control cell lines with D9 conﬁrmed that the change in sensitivity
was due to ME1 expression changes and not a result of the vector
(Supplementary Fig. S9e–S9f).Taken together, these results demonstrate a shift in redox homeostasis in the absence of ME1 expression
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Figure 4.
ME1 absence in SS results in altered redox homeostasis and iron redox status. A, Metabolite levels (pmol/106 cells) of reduced glutathione (GSH; top) and
oxidized glutathione (GSSG; bottom) in ME1-null SS cell lines (SYO-1 WT and Fuji WT) and ME1-overexpressing cell lines (SYO-1 OE and Fuji OE). Data, mean  SD
(n ¼ 6);   , P < 0.001. B, Average normalized isotopomer abundance from stable isotope tracing of U13C-glutamine in reduced glutathione (GSH; top) and
oxidized glutathione (GSSG; bottom) over time in ME1-null SS cell line SYO-1 WT and ME1-overexpressing cell line SYO-1 OE. Isotopomer abundance was normalized
to cell count. (Continued on the following page.)
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Malic Enzyme 1 Absence Increases Ferroptosis Sensitivity

ME1 absence sensitizes cells to ferroptotic cell death with
erastin
Elevated levels of ROS and increases in the labile iron pool are both
associated with susceptibility to cell death by ferroptosis (37, 68).
Therefore, it was hypothesized that ME1-null cells would exhibit
increased sensitivity to erastin, an established inducer of ferroptosis (69, 70). Cell death with erastin treatment was compared in ME1expressing cells (SYO OE, Fuji OE, and HTB93 WT) and ME1-null or
-deﬁcient cells (SYO WT, Fuji WT, and HTB-93 KD2 and KD3).
Treatment with erastin resulted in signiﬁcantly increased cell death in
cells that do not express ME1 (SYO-1 WT and Fuji WT) compared
with ME1-overexpressing cells (SYO-1 OE and Fuji OE; Fig. 5A
and B). However, partial KD of ME1 in HTB-93 was likely not
sufﬁcient to induce signiﬁcantly higher levels of cell death with erastin

relative to HTB-93 WT cell lines (Supplementary Fig. S12a). Treatment of vector control cell lines with erastin conﬁrmed that changes in
sensitivity to erastin treatment were dependent upon ME1 expression
and were unrelated to the vector (Supplementary Fig. S13a and S13b).
Ferroptosis is often associated with high levels of lipid peroxidation;
therefore, the lipid peroxidation-mediated cell death in response to
erastin was investigated in WT ME1-null SS (71–73). Cell death with
erastin in combination with lipophilic antioxidants (Trolox and alphatocopherol) and ferrostatin was compared with treatment with erastin
alone. Cotreatment with lipophilic antioxidants as well as ferrostatin
signiﬁcantly attenuated cell death in both SYO-1 WT ME1-null and
Fuji WT ME1-null cells (Fig. 5C and D). Furthermore, lipid peroxidation with and without erastin treatment was measured using the
Image-IT live-cell imaging probe. As expected, erastin treatment
induced signiﬁcantly more lipid peroxidation in cells that do not
express ME1 when compared with ME1-expressing cells (Fig. 5E
and F). Similarly, erastin treatment resulted in signiﬁcantly more lipid
peroxidation in HTB-93 ME1 KD cells relative to HTB-93 WT cells
(Supplementary Fig. S12b). Cumulatively these data indicate that
erastin induces cell death via a lipid peroxidation-dependent mechanism, and the attenuation of cell death in response to ferrostatin
suggests that cell death occurs through ferroptosis.
Accumulation of iron is a common feature of cancer metabolism,
which can not only fuel ROS production leading to ferroptosis, but also
contributes to cellular growth and cell survival (39). Therefore, cellular
dependence on elevated labile iron pools in the context of ME1 absence
was evaluated. Deferasirox, a nonredox active iron chelator, was used
to chelate the free iron, and cellular response in SS WT ME1-null and
ME1 OE cell lines was compared. Death was signiﬁcantly induced in
both SYO-1 and Fuji WT ME1-null lines, whereas minimal cell death
was induced in the ME1-OE cell lines (Fig. 5G). Additionally, when
ME1 was knocked down in HTB-93, these cells became sensitive to
deferasirox treatment (Fig. 5H; Supplementary Fig. S14a). Treatment
of vector control cell lines with deferasirox conﬁrmed that changes in
sensitivity to deferasirox treatment were dependent upon ME1 expression and were unrelated to the vector (Supplementary Fig. S14b and
S14c). These data establish that ME1-null cells are dependent upon
labile iron pools. This dependency suggests that escape from ferroptosis induction is not likely achievable through reductions to labile iron
pool in this context. Collectively these data support the exploration of
ferroptosis induction as a viable translational target for ME1-null SS.
Exploiting alterations in ROS homeostasis and the glutathione/
thioredoxin axis at cystine import
The proposed mechanism of erastin is inhibition of cystine import
through xCT, leading to lipid peroxidation and ferroptosis (Fig. 6A;
ref. 37). Cystine imported by xCT is rapidly converted to cysteine in the
intracellular environment. Within this study, it has been demonstrated

(Continued.) C, Average normalized isotopomer abundance from stable isotope tracing of U13C-glutamine in reduced glutathione (GSH; top) and oxidized
glutathione (GSSG; bottom) over time in ME1-null SS cell line Fuji WT and ME1-overexpressing cell line Fuji OE. Isotopomer abundance was normalized
to cell count. D, In vitro cell death response to BSO inhibition of gamma-glutamyl l in ME1-null SS cell lines (SYO-1 WT and Fuji WT), ME1 overexpression cell lines (SYO-1 OE and Fuji OE), ME1-expressing cell lines (HTB-93 WT), and ME1 KD cell lines (HTB-93 KD1). Data, mean  SD (n ¼ 3);     , P < 0.0001;

, P < 0.001;   , P < 0.01. E, Relative ﬂuorescence measurements (RFU) of global thiol levels to treatment with BSO relative to no treatment (NT) in
ME1-null SS cell line SYO-1 WT and ME1-overexpressing cell line SYO-1 OE. Data, mean  SD (n ¼ 3);   , P < 0.01;    , P < 0.0001. F, Relative ﬂuorescence
measurements (RFU) of global thiol levels to treatment with BSO relative to NT in ME1-null SS cell line Fuji WT and ME1-overexpressing cell line Fuji OE.
Data, mean  SD (n ¼ 3);    , P < 0.001;     , P < 0.0001. G, In vitro cell death response to D9 inhibition of thioredoxin reductase in ME1-null SS cell lines
(SYO-1 WT, Fuji WT), ME1 overexpression cell lines (SYO-1 OE and Fuji OE), ME1-expressing cell line (HTB-93 WT), and ME1 KD cell line (HTB-93 KD1).
Data, mean  SD (n ¼ 3);     , P < 0.0001;   , P < 0.01. H, Relative fold change of H2O2 in ME1-null SS cell lines (SYO-1 WT and Fuji WT) and ME1
overexpression cell lines (SYO-1 OE and Fuji OE). Data, mean  SD (n ¼ 3);   , P < 0.01. I, Relative fold change of Fe2þ levels in ME1-null SS cell lines (SYO-1 WT
and Fuji WT) and ME1 overexpression cell lines (SYO-1 OE and Fuji OE) at baseline. Data, mean  SD (n ¼ 3);   , P < 0.01;    , P < 0.001.
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in SS. Speciﬁcally, the overall activity of the glutathione antioxidant system is reduced and sensitivity to inhibition of gammaglutamylcysteine ligase is reduced, whereas sensitivity to inhibition
of the thioredoxin system is increased in the absence of ME1. These
data suggest that in the absence of ME1 expression in SS, the
thioredoxin pathway is more essential for the maintenance of
redox homeostasis than the glutathione pathway (Fig. 4G).
Due to the shift from glutathione to thioredoxin sensitivity, the
impact on ROS levels was assessed, speciﬁcally H2O2. The glutathione
antioxidant pathway plays a large role in managing H2O2, primarily
through supporting the activity of glutathione peroxidases (32, 66).
Therefore, a ﬂuorescent probe was used to evaluate differences in
baseline levels of H2O2 between WT ME1-null and ME1 OE cell lines.
Consistent with reduced glutathione pathway activity, these data
demonstrated that WT ME1-null SS cell lines have an increased level
of intracellular H2O2 when compared with ME1 OE cell lines at
baseline (Fig. 4H). It was hypothesized that the Fenton reaction, a
pathway that depends upon H2O2 levels and free iron levels, would
have increased ﬂux as a result of the increased H2O2 burden (67).
Essential components of the Fenton reaction were examined by
baseline measurements of Fe2þ and Fe3þ (Fig. 4I; Supplementary
Fig. S11). At baseline, WT cells have increased levels of Fe2þ compared
with ME1-OE cells (Fig. 4I), whereas relative levels of Fe3þ are
equivalent (Supplementary Fig. S11). Taken together, increased intracellular H2O2 levels and elevations in labile Fe2þ suggest increased
potential for ROS production by the Fenton reaction (67). Collectively,
these data indicate complex shifts in redox homeostasis in the context
of ME1 absence, such that the dependency upon the thioredoxin
pathway is enhanced whereas activity of the glutathione pathway is
substantially reduced. Reductions in glutathione pathway activity are
also evidenced in elevated levels of H2O2. These changes, combined
with concomitant increases in the labile iron pool, suggested enhanced
susceptibility to oxidative stress in cells that lack ME1 expression.
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Figure 6.
Exploiting alterations in ROS homeostasis and the glutathione/thioredoxin axis at cystine import. A, Schematic diagram: xCT: glutamine-cystine antiporter
(SLC3A2 and SLC7A11); ME1: malic enzyme 1; GSH: representing glutathione antioxidant system; thioredoxin: representing thioredoxin antioxidant system.
B, In vitro cell death in response to ACXT-3102 (Sigma-2/erastin) inhibition of xCT in ME1-null SS cell lines (SYO-1 WT and Fuji WT) and ME1-overexpressing
cell lines (SYO-1 OE and Fuji OE). Data, mean  SD (n ¼ 3);     , P < 0.0001. C, Tumor volume of SYO-1 WT ME1-null xenografts treated until day 12 with
ACXT-3102 (n ¼ 10) (ACXT-3102) or vehicle (n ¼ 10). Data, mean  SEM;    , P < 0.0001. D, Tumor volume of SYO-1 ME1-OE xenografts treated until day 12
with ACXT-3102 (n ¼ 10) (ACXT-3102) or vehicle (n ¼ 10). Data, mean  SEM; NS, P > 0.05.

that ME1-deﬁcient cells exhibit changes to systems that depend on
intracellular cysteine, the thioredoxin and glutathione systems. Therefore, cysteine metabolism may also contribute to increased erastin
sensitivity in cells that lack expression of ME1. Cystine uptake was

measured using an FITC-cystine probe in SS WT ME1-null and ME1
OE cell lines, revealing that ME1 expression does not alter cystine
uptake rates in SS (Supplementary Fig. S15a and S15b). However,
measurements of intracellular cysteine via mass spectrometry revealed

Figure 5.
ME1 absence sensitizes cells to ferroptotic cell death with erastin. A, In vitro cell death in response to erastin (1 mmol/L) in ME1-null SS cell line SYO-1 WT and ME1
overexpression cell line SYO-1 OE. Data, mean  SD (n ¼ 3);     , P < 0.0001; NS, P > 0.05. B, In vitro cell death in response to erastin (2 mmol/L) in the ME1-null SS cell
line Fuji WT and ME1 overexpression cell line Fuji OE. Data, mean  SD (n ¼ 3);  , P < 0.05; NS, P > 0.05. C, In vitro cell death in response to erastin (1 mmol/L)  Trolox,
a-tocopherol (a-Toc), or ferrostatin in ME1-null SS cell line SYO-1. Data, mean  SD (n ¼ 3);   , P < 0.01; NS, P > 0.05. D, In vitro cell death in response to erastin
(2 mmol/L)  Trolox, a-tocopherol (a-Toc), or ferrostatin in ME1-null SS cell line Fuji WT. Data, mean  SD (n ¼ 3);   , P < 0.01;  , P < 0.05; NS, P > 0.05. E, Relative
ﬂuorescence measurements (RFU) of lipid peroxidation to treatment with erastin (1 mmol/L) relative to NT in ME1-null SS cell line SYO-1 WT and ME1-overexpressing
cell line SYO-1 OE. Data, mean  SD (n ¼ 3);    , P < 0.001;   , P < 0.01. F, Relative ﬂuorescence measurements (RFU) of lipid peroxidation to treatment with erastin
(4 mmol/L) relative to NT in ME1-null SS cell line Fuji WT and ME1-overexpressing cell line Fuji OE. Data, mean  SD (n ¼ 3);   , P < 0.01; NS, P > 0.05. G, In vitro cell death
in response to deferasirox iron chelation in ME1-null SS cell lines (SYO-1 WT and Fuji WT) and ME1 overexpression cell lines (SYO-1 OE and Fuji OE). Data, mean  SD
(n ¼ 3);    , P < 0.0001. H, In vitro cell death in response to deferasirox iron chelation in ME1-expressing cell lines (HTB-93 WT) and ME1-KD cell lines (HTB-93 KD1).
Data are represented as mean  SD (n ¼ 3);     , P < 0.0001.
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Discussion
SS arises from a characteristic chromosomal translocation between
SS18 and SSX that drives broad changes in chromatin remodeling and
gene transcription (78). As there is a clinical need for the development
of highly effective, targeted therapeutics for SS, we hypothesized that
understanding SS metabolism would reveal a therapeutic opportunity.
Within this study, metabolic characterization identiﬁed SS as the ﬁrst
cancer that recurrently lacks expression of ME1. Although cancers
have been associated with an overexpression in ME1, this is the ﬁrst-inclass example of a cancer that consistently lacks expression of ME1.
Cancer metabolism is often inherited from the cell of origin (79, 80).
Consistent with this body of literature, we demonstrated that the
absence of ME1 expression in SS appears to be linked to the absence of
ME1 in the recently proposed cell of origin; however, determination of
the cell of origin for SS is an active ﬁeld an additional research may be
necessary to corroborate this ﬁnding in future studies (81). Without
ME1 expression, SS exhibits increased reliance on the thioredoxin
pathway and alterations in iron redox biology. Therefore, these ﬁndings provide a rationale for the utilization of therapies to exploit the
innate redox biology in ME1-null cancers.
Metabolomic analysis of ME1-null SS cell lines revealed that glucose
catabolism occurred primarily through glycolysis, and that glucose was
preferentially directed through the oxPPP. Increased ﬂux of glucose
through the oxPPP contributes to the production of NADPH in the
absence of ME1. Disrupting the ability of SS to produce NADPH
through the oxPPP by inhibiting G6PD with G6PDi-1 resulted in cell
death in vitro. This correlates with previous ﬁndings that knockdown
of ME1 in ME1-overexpressing cancers altered cellular NADPH
production and increased dependency upon the oxPPP (18, 59).
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ME1 knockdown results in a depletion of total cellular GSH,
suggesting altered redox biology related to the glutathione pathway.
We have found that ME1-null SS exhibits an underactive glutathione
pathway, whereas dependence upon thioredoxin pathway activity is
signiﬁcantly increased in the context of ME1 absence. Preferential
utilization of the thioredoxin pathway over the glutathione pathway
for the maintenance of redox homeostasis has been described in the
literature, but the underlying mechanisms are poorly understood (82, 83). More studies are needed to fully understand the role
of the thioredoxin system in ME1-deﬁcient cancers. However, this
work contributes to the growing body of evidence that emphasizes the
importance of the thioredoxin system as a potential therapeutic target
in cancer (84–86).
ME1 knockdowns have demonstrated increased sensitivity to redox
stress (18). Similarly, we have identiﬁed key metabolic alterations that
increase baseline ROS and susceptibility to the induction of redox
stress in ME1-null SS. ME1-null SS exhibits increased H2O2 and labile
iron pools, which promote Fenton reaction activity and ROS accumulation. Consistent with the demonstrated increase in ROS and liable
iron pools, ME1-null SS exhibits increased sensitivity to erastininduced lipid peroxidation and ferroptosis. Critically, the enhanced
dependency upon an elevated labile iron pool coupled with reduced
glutathione pathway capacity uniquely primes ME1-null SS for ferroptosis induction and supports the development of treatment strategies targeting the ferroptotic pathway in SS.
Erastin has underperformed in clinical trials, and this lack of efﬁcacy
is due to the inability of the drug to be efﬁciently taken up by cancer
cells (76). This uptake blockade can be overcome by conjugating
erastin to a sigma-2 ligand to enhance xCT receptor interaction. This
conjugation forms a more efﬁcacious construct, Sigma-2/erastin
(ACXT-3102; refs. 76, 77, 87–92). Inhibition of xCT with ACXT3102 induced rapid death in WT ME1-null SS cells, and cell death was
protected by ME1 expression. Furthermore, in SYO-1 WT ME1-null
xenografts, ACXT-3102 treatment signiﬁcantly impaired tumor
growth. Importantly, SYO-1 ME1 OE xenograft mice did not exhibit
signiﬁcant tumor response to treatment with ACXT-3102 at the
dosage used. These data indicate that ME1 absence is a predictive
biomarker for sensitivity to xCT inhibition and further support the
development of treatment strategies targeting the ferroptotic pathway
in SS.
This study is the ﬁrst to characterize the metabolism of synovial
sarcoma. Within this study, novel metabolic vulnerabilities have been
uncovered in SS. Importantly, the recurrent absence of ME1 has been
identiﬁed in SS. Although studies have demonstrated that ME1 is
frequently overexpressed in cancer, this is the ﬁrst study to identify a
cancer where ME1 is not expressed recurrently and predictably. ME1 is
thought to play an essential role in maintaining redox homeostasis
within the cell. With insufﬁcient expression of ME1, ME1-null SS
adapts to maintain the redox homeostasis; however, these adaptations
can be easily disrupted. By exploiting alterations in redox homeostasis
with ACXT-3102 inhibition of xCT, a new treatment strategy for ME1null cancers can be developed. Additionally, inhibition of xCT could
provide a targeted treatment for a broader group of patients with
cancers overexpressing ME1; however, these ﬁndings await the identiﬁcation of a selective ME1 inhibitor, which is currently under
development.
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that ME1-null cells exhibit signiﬁcantly reduced intracellular cysteine
pools compared with ME1-expressing SS (Supplementary Fig. S15c).
These data suggest that elevated demand for intracellular cysteine to
fuel cellular antioxidant systems may also contribute to increased
erastin sensitivity in WT ME1-null compared with ME1 OE SS cells.
Erastin, although a potent inhibitor of xCT in vitro, has failed to
translate clinically in human trials, likely due to poor tumor targeting
and uptake (74, 75). Therefore, to evaluate the effect of xCT inhibition
with a clinically relevant compound in vivo, the efﬁcacy of an erastin
conjugate molecule, ACXT-3102 in WT ME1-null and ME1 OE SS cell
lines was tested. ACXT-3102 is a sigma-2 ligand-conjugated erastin
compound with increased intracellular import, which similarly inhibits xCT (76, 77). As expected, treatment with ACXT-3102 recapitulated the cell death response induced by erastin, demonstrating
higher levels of cell death in WT ME1-null SS cells relative to ME1
OE SS cells (Fig. 6B).
Furthermore, to evaluate the in vivo efﬁcacy of ACXT-3102 treatment in SYO-1 WT ME1-null and ME1 OE in vivo. Xenografts were
grown to 200 mm3 prior to treatment initiation with oral ACXT-3102
for 12 days at 60 mg/kg. The effect on tumor growth was measured
daily (Fig. 6C and D). Relative to vehicle-treated xenografts (n ¼ 10),
the growth of SYO-1 WT ME1-null tumors treated with ACXT-3102
(n ¼ 10) was inhibited (Fig. 6C). However, treatment with ACXT3102 failed to inhibit tumor growth in SYO-1 OE tumors (n ¼ 10),
resulting in no signiﬁcant difference between the vehicle-treated
xenografts (n ¼ 10) and the ACXT-3102-treated xenografts at the
dose utilized (Fig. 6D). These data suggest that not only is disruption of
redox homeostasis using xCT inhibition a valid translational target in
SS, but that the response to xCT inhibition in this context is dependent
upon the ME1 expression status of the tumor.
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